NYSE · ABBV
AbbVie Inc.
Healthcare · Drug Manufacturers - General
$262.82▲ 1.11% ($2.89)at close
As of 4:02 PM ET
Market cap
$464.35B
P/E
Valuation
Revenue & margin DCF
Verdict: fairly priced. Price above Base.
The price needs 7.5% revenue growth a year for 10 years. Our scenarios assume 2.5–4.5%.
That's 3.5× its past 4-year pace.
Value per share
Base case
$181.59
Price used $262.82 is 45% above this
USD · TTM ending Jun 30, 2026 · Price Oct 2, 8:02 PM UTC
Revenue each value needs
Revenue today $64.4B. The price needs $132B by 2036. Base case: $90B. At its recent pace: $79.6B. Bear to Bull: $82B to $100B.
Revenue today $64.4B. The price needs $132B by 2036. Base case: $90B. At its recent pace: $79.6B. Bear to Bull: $82B to $100B.
Revenue in 2036
today $64.4B
+$42.2Bmore than the Base case · 1.5×
Value per share · Base case
$181.59
Price $262.82
45% above this
- 10-yr revenue CAGR
- 3.4%
- Ending operating margin
- 29.3%
- Discount rate
- 7.4%
USD · TTM ending Jun 30, 2026 · Price Oct 2, 8:02 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 11.1% over the last year. Revenue grew 10.39% over the trailing twelve months. Operating margin moved from 18.8% to 29.32%. Free cash flow grew 7.91% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 29.32%. A decisive move in revenue — currently up 10.39% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
31
Buy
11
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Oct 30, 2026
Q3 FY26 · EPS est $3.86 · Revenue est $17.31B
View
Institutional Sentiment
AbbVie Inc. · ABBV
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.